Synjardy is used with diet and exercise to help improve blood sugar control in people with type 2 diabetes. If you are asking what is Synjardy used for, the direct answer is that it combines two oral diabetes medicines, empagliflozin and metformin, in one tablet. It is not insulin. It is also not used to treat type 1 diabetes or diabetic ketoacidosis. Why this matters: the combination may fit some treatment plans, but kidney function, dehydration risk, genital or urinary infections, and stomach-related side effects should be reviewed before and during use.
Key Takeaways
- Synjardy combines empagliflozin and metformin for type 2 diabetes blood sugar management.
- Empagliflozin is an SGLT2 inhibitor, while metformin is a biguanide.
- Synjardy XR contains the same active medicines in an extended-release form.
- Side effects can include stomach upset, urinary symptoms, genital yeast infections, and dehydration.
- Dose, formulation, and monitoring should be individualized by the prescribing clinician.
What Synjardy Does in Diabetes Care
Synjardy helps lower blood glucose through two different mechanisms. Metformin reduces how much glucose the liver releases and can improve the body’s response to insulin. Empagliflozin helps the kidneys remove extra glucose through urine by blocking sodium-glucose cotransporter 2, often shortened to SGLT2.
At a practical level, what is Synjardy used for depends on the treatment goal. A clinician may consider it when a person with type 2 diabetes needs both metformin and an SGLT2 inhibitor as part of a broader plan. That plan still usually includes nutrition choices, physical activity when appropriate, glucose monitoring, and periodic lab review.
This combination does not replace insulin when insulin is medically needed. It also does not treat type 1 diabetes, where the body makes little or no insulin. For a closer look at the tablet-strength topic, see Synjardy 12.5 mg 1000 mg.
Why it matters: Knowing the two ingredients helps explain both the benefits and the cautions.
Why Empagliflozin and Metformin Are Combined
The combination can be useful because the two ingredients act in different parts of glucose regulation. Metformin mainly affects liver glucose output and insulin sensitivity. Empagliflozin mainly affects kidney glucose reabsorption, which allows more glucose to leave the body in urine.
Using two mechanisms in one tablet may simplify some treatment plans. It can also reduce the need to manage two separate prescriptions. That does not mean the combination is automatically better for every person. Treatment choice depends on A1C, kidney function, cardiovascular and kidney history, side effect history, other medicines, cost and access, and personal preferences.
Some people may use metformin alone. Others may need another add-on medicine, injectable therapy, or insulin. The right approach depends on the clinical picture, not just the medication name. For class-level background, SGLT2 Inhibitors Explained covers how this group of medicines fits into type 2 diabetes care. For the active ingredient specifically, see Empagliflozin Uses.
Synjardy XR, Jardiance, Metformin, and Ozempic
Many questions about this medicine come from similar names. The key difference is whether the medicine contains one ingredient, two ingredients, or belongs to a different drug class.
| Medicine or topic | What it means | Why the difference matters |
|---|---|---|
| Synjardy | Contains empagliflozin plus metformin. | It combines an SGLT2 inhibitor with metformin in one oral medicine. |
| Synjardy XR | Contains the same active ingredients in an extended-release form. | The release pattern and instructions differ from immediate-release tablets. |
| Jardiance | Contains empagliflozin without metformin. | It may be considered when metformin is not part of the plan or is prescribed separately. |
| Metformin | Contains one biguanide medicine. | It is often a foundation therapy, but it does not include an SGLT2 inhibitor. |
| Ozempic | Contains semaglutide, a GLP-1 receptor agonist. | It is not the same medicine or drug class as Synjardy. |
The Jardiance comparison can be confusing because both Jardiance and Synjardy contain empagliflozin. Jardiance is the single-ingredient product, while Synjardy pairs empagliflozin with metformin. Product pages such as Jardiance and Metformin can help readers identify the specific medicine being discussed, but prescribing decisions still belong with a healthcare professional.
Synjardy is also not the same as Ozempic. Ozempic is a semaglutide injection in the GLP-1 receptor agonist class. GLP-1 medicines affect appetite, insulin release, and glucagon signaling in different ways. Synjardy is an oral empagliflozin-metformin combination, so the expected benefits, risks, and monitoring needs are different.
Benefits, Weight Effects, and Limits
The main benefit of Synjardy is improved blood sugar control in type 2 diabetes when the combination is appropriate. For many readers, what is Synjardy used for also leads to questions about weight, heart health, and kidney considerations. Those topics matter, but they should not be separated from the person’s full diabetes plan.
Some people may notice modest weight change with SGLT2 inhibitor therapy because glucose leaves the body through urine. That effect varies. Synjardy is not a weight loss drug, and weight change should not be treated as guaranteed. If weight is part of the treatment discussion, it should be reviewed alongside food intake, activity, glucose trends, kidney function, and other medicines.
People using insulin or sulfonylureas may need closer review if food intake, activity, or body weight changes. Those medicines can raise the chance of hypoglycemia, meaning low blood glucose. Symptoms may include shakiness, sweating, confusion, hunger, or fast heartbeat.
There may also be heart and kidney considerations in type 2 diabetes care. Empagliflozin has evidence and approved uses in selected cardiovascular and kidney-related settings, depending on the product label and jurisdiction. Whether that applies to a specific Synjardy plan should be discussed with the prescriber, because the metformin component and kidney function still matter.
For a focused discussion of the weight topic, see Synjardy Weight Loss.
Side Effects and Safety Issues to Review
Synjardy side effects can come from either ingredient. Metformin commonly causes digestive effects, especially nausea, diarrhea, gas, or abdominal discomfort. These symptoms can be more noticeable when starting treatment or after a dose change. Taking metformin-containing medicines with food may reduce stomach upset for some people, but the prescription label should guide use.
Empagliflozin can increase urination because it helps remove glucose through urine. This can contribute to thirst, dehydration, dizziness, or low blood pressure in some people. The same urine-glucose effect can increase the risk of genital yeast infections. Urinary tract infections can also occur.
Common effects to ask about
- Digestive symptoms: nausea, diarrhea, or stomach discomfort.
- Urinary changes: increased urination or urgency.
- Genital symptoms: itching, redness, discharge, or irritation.
- Hydration concerns: dizziness, thirst, or lightheadedness.
- Low glucose risk: more likely with insulin or sulfonylureas.
Side effects in men can include genital yeast infection symptoms, such as redness, itching, irritation, swelling, or discharge. These symptoms are not limited to men. Anyone with genital or urinary symptoms should contact a healthcare professional for proper evaluation, especially if symptoms are severe or keep returning.
Serious symptoms need prompt review
Some reactions are uncommon but important. SGLT2 inhibitors can be linked with ketoacidosis, a dangerous acid buildup that may occur even when glucose is not extremely high. Warning signs can include nausea, vomiting, abdominal pain, unusual tiredness, trouble breathing, or confusion. Metformin has a rare but serious warning for lactic acidosis, another acid buildup risk, especially when kidney function is poor or during severe illness. For more context, read Lactic Acidosis and Metformin.
Seek urgent medical help for severe dehydration, fainting, breathing trouble, confusion, severe abdominal pain, or symptoms of a serious allergic reaction. Pain, swelling, tenderness, redness, or fever around the genital or perineal area also needs urgent care because rare severe infections have been reported with SGLT2 inhibitors.
How It Is Taken and Monitored
Synjardy dosing is individualized. Clinicians consider current diabetes medicines, kidney function, tolerability, glucose readings, and the selected formulation. Search terms such as Synjardy dosage or Synjardy 12.5 mg/1000 mg side effects can be misleading because tablet strength alone does not determine whether the medicine is appropriate.
Synjardy XR is the extended-release version. Extended-release tablets are designed to release medicine over time, so they should not be crushed, split, or chewed unless the product instructions specifically allow it. People should not change from immediate-release tablets to the XR form, change frequency, or take extra doses without prescriber guidance.
Monitoring usually focuses on A1C, day-to-day glucose patterns, kidney function, hydration status, and side effects. Some people may also need vitamin B12 review over time because long-term metformin use can be associated with lower B12 levels. A1C gives a longer-range view of glucose exposure than a single finger-stick reading.
The calculator below can convert A1C and estimated average glucose for general context. It does not set targets, confirm treatment response, or replace clinician guidance.
HbA1c & eAG Calculator
Convert between HbA1c percentage and estimated average glucose using the ADAG relationship.
These calculations are for education only and do not replace clinical advice, diagnosis, or treatment. Always confirm medical decisions with a qualified healthcare professional.
Quick tip: Bring recent glucose logs and lab results to medication reviews.
Who May Need Extra Review Before Use?
Some people need closer review before using an empagliflozin-metformin combination. Kidney function is central because both active ingredients have kidney-related considerations. A prescriber may also reassess use during severe illness, dehydration, surgery, fasting, or very low-carbohydrate eating patterns, because these situations can change risk.
Synjardy is not appropriate for diabetic ketoacidosis. People with a history of frequent genital infections, recurrent urinary tract infections, dehydration, low blood pressure, heavy alcohol use, liver concerns, or serious acute illness should make sure those issues are reviewed. Pregnancy, plans for pregnancy, and breastfeeding also need clinician guidance.
Medication interactions matter too. Insulin and sulfonylureas can increase the chance of low blood sugar when used with other glucose-lowering medicines. Diuretics, blood pressure medicines, kidney-affecting drugs, and contrast imaging procedures may also affect monitoring plans. This does not mean these combinations are never used, but they need prescriber oversight.
Questions to Prepare Before a Medication Review
When asking what is Synjardy used for, prepare questions that connect the medicine to your specific treatment plan. The goal is not just to know the drug name. It is to understand why this combination was chosen, what monitoring is expected, and which symptoms should prompt follow-up.
- Glucose goal: what A1C or glucose range is being targeted?
- Kidney review: what recent kidney tests support this choice?
- Formulation choice: why immediate-release or XR?
- Side effect plan: which symptoms need same-day advice?
- Other medicines: how will insulin or sulfonylureas be managed?
- Sick-day planning: what should happen during vomiting, dehydration, or surgery?
If a prescription is involved, the Synjardy product page can help identify the specific medication being reviewed. Where required, CanadianInsulin.com may help confirm prescription details with the prescriber, while dispensing and fulfilment are handled by licensed third-party pharmacies where permitted.
For broader browsing across related diabetes categories, the Type 2 Diabetes collection lists relevant medication options in one place. The Type 2 Diabetes Articles category can also support general learning before a medication review.
Authoritative Sources
- European Medicines Agency medicine overview for ingredient and approved-use context.
- DailyMed medication guide for Synjardy for patient-facing safety information.
- American Diabetes Association Standards of Care for type 2 diabetes treatment principles.
This content is for informational purposes only and is not a substitute for professional medical advice.
